Equities research analysts predict that Amneal Pharmaceuticals, Inc. (NYSE:AMRX – Get Rating) will report sales of $500.68 million for the current quarter, Zacks reports. Four analysts have provided estimates for Amneal Pharmaceuticals’ earnings, with the highest sales estimate coming in at $508.70 million and the lowest estimate coming in at $493.50 million. Amneal Pharmaceuticals reported sales of $493.11 million during the same quarter last year, which indicates a positive year-over-year growth rate of 1.5%. The firm is expected to announce its next quarterly earnings report before the market opens on Monday, January 1st.
On average, analysts expect that Amneal Pharmaceuticals will report full year sales of $2.19 billion for the current fiscal year, with estimates ranging from $2.18 billion to $2.21 billion. For the next year, analysts expect that the company will report sales of $2.28 billion, with estimates ranging from $2.25 billion to $2.29 billion. Zacks’ sales calculations are an average based on a survey of research firms that follow Amneal Pharmaceuticals.
Amneal Pharmaceuticals (NYSE:AMRX – Get Rating) last posted its quarterly earnings data on Wednesday, March 2nd. The company reported $0.18 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.20 by ($0.02). Amneal Pharmaceuticals had a return on equity of 61.08% and a net margin of 0.68%. The firm had revenue of $537.00 million for the quarter, compared to analysts’ expectations of $533.41 million. During the same quarter last year, the firm posted $0.11 earnings per share. Amneal Pharmaceuticals’s quarterly revenue was up 5.3% on a year-over-year basis.
Several institutional investors have recently modified their holdings of AMRX. Covestor Ltd acquired a new position in shares of Amneal Pharmaceuticals during the 4th quarter worth approximately $32,000. Harel Insurance Investments & Financial Services Ltd. lifted its holdings in Amneal Pharmaceuticals by 55.1% in the fourth quarter. Harel Insurance Investments & Financial Services Ltd. now owns 8,388 shares of the company’s stock valued at $41,000 after acquiring an additional 2,979 shares during the last quarter. Lazard Asset Management LLC lifted its holdings in Amneal Pharmaceuticals by 24.1% in the fourth quarter. Lazard Asset Management LLC now owns 12,834 shares of the company’s stock valued at $61,000 after acquiring an additional 2,494 shares during the last quarter. CIBC Asset Management Inc lifted its holdings in Amneal Pharmaceuticals by 16.6% in the third quarter. CIBC Asset Management Inc now owns 14,238 shares of the company’s stock valued at $76,000 after acquiring an additional 2,024 shares during the last quarter. Finally, Teacher Retirement System of Texas lifted its holdings in Amneal Pharmaceuticals by 26.2% in the third quarter. Teacher Retirement System of Texas now owns 15,487 shares of the company’s stock valued at $83,000 after acquiring an additional 3,216 shares during the last quarter. Institutional investors and hedge funds own 38.54% of the company’s stock.
NYSE:AMRX opened at $4.12 on Monday. Amneal Pharmaceuticals has a 12 month low of $3.86 and a 12 month high of $6.21. The stock has a 50 day moving average of $4.31 and a two-hundred day moving average of $4.68. The company has a current ratio of 2.35, a quick ratio of 1.57 and a debt-to-equity ratio of 7.11. The firm has a market cap of $1.24 billion, a P/E ratio of 45.78, a price-to-earnings-growth ratio of 0.22 and a beta of 1.24.
About Amneal Pharmaceuticals (Get Rating)
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.
- Get a free copy of the StockNews.com research report on Amneal Pharmaceuticals (AMRX)
- Institutions And Analysts Drive UnitedHealth Group Higher
- MarketBeat: Week in Review 4/11 – 4/15
- Three Beaten Down Mega Caps The Analysts Are Upgrading
- Top 3 Safe Stocks for Conservative Investors
- Array Technologies Stock Giving Another Ground Floor Entry
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.